(0.00%) 5 187.67 points
(0.44%) 39 056 points
(-0.18%) 16 303 points
(0.37%) $79.28
(-0.37%) $2.18
(-0.16%) $2 318.70
(0.25%) $27.67
(0.27%) $987.30
(0.04%) $0.930
(0.08%) $10.90
(0.02%) $0.800
(0.00%) $91.74
Live Chart Being Loaded With Signals
FDC Limited manufactures and markets pharmaceutical products in India and internationally. The company offers specialized formulations for various therapeutic segments, including anti-infective, gastrointestinal, ophthalmological, vitamins/minerals/dietary supplements, cardiac, anti-diabetes, respiratory, gynecology, dermatology, analgesics, and others; and oral rehydration salts...
Stats | |
---|---|
本日の出来高 | 97 215.00 |
平均出来高 | 178 915 |
時価総額 | 73.54B |
EPS | INR0 ( 2024-02-06 ) |
次の収益日 | ( INR0 ) 2024-05-22 |
Last Dividend | INR0.800 ( 2020-03-19 ) |
Next Dividend | INR0 ( N/A ) |
P/E | 25.43 |
ATR14 | INR0.416 (0.09%) |
ボリューム 相関
FDC Limited 相関
10 最も正の相関 | |
---|---|
KOTAKBANK.NS | 0.848 |
MAXVIL.NS | 0.806 |
10 最も負の相関 | |
---|---|
GANGOTRI.NS | -0.83 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
FDC Limited 相関 - 通貨/商品
FDC Limited 財務諸表
Annual | 2022 |
収益: | INR17.84B |
総利益: | INR11.28B (63.24 %) |
EPS: | INR11.67 |
FY | 2022 |
収益: | INR17.84B |
総利益: | INR11.28B (63.24 %) |
EPS: | INR11.67 |
FY | 2022 |
収益: | INR15.26B |
総利益: | INR9.78B (64.12 %) |
EPS: | INR12.82 |
FY | 2021 |
収益: | INR13.27B |
総利益: | INR9.00B (67.82 %) |
EPS: | INR17.72 |
Financial Reports:
No articles found.
FDC Limited Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
First Dividend | INR0.100 | 2002-08-19 |
Last Dividend | INR0.800 | 2020-03-19 |
Next Dividend | INR0 | N/A |
Payout Date | 2020-03-26 | |
Next Payout Date | N/A | |
# dividends | 20 | -- |
Total Paid Out | INR24.83 | -- |
Avg. Dividend % Per Year | 0.03% | -- |
Score | 1.7 | -- |
Div. Sustainability Score | 4.35 | |
Div.Growth Potential Score | 4.24 | |
Div. Directional Score | 4.30 | -- |
Year | Amount | Yield |
---|---|---|
2002 | INR0 | 0.00% |
2003 | INR0 | 0.00% |
2004 | INR0 | 0.00% |
2005 | INR0 | 0.00% |
2006 | INR0 | 0.00% |
2007 | INR0 | 0.00% |
2008 | INR0 | 0.00% |
2009 | INR0 | 0.00% |
2010 | INR0 | 0.00% |
2011 | INR0 | 0.00% |
2012 | INR0 | 0.00% |
2013 | INR0 | 0.00% |
2014 | INR0 | 0.00% |
2015 | INR0 | 0.00% |
2016 | INR0 | 0.00% |
2017 | INR0 | 0.00% |
2018 | INR0 | 0.00% |
2019 | INR0 | 0.00% |
2020 | INR0.800 | 0.38% |
2021 | INR0 | 0.00% |
2022 | INR0 | 0.00% |
2023 | INR0 | 0.00% |
2024 | INR0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
SIYSIL.NS | Dividend Junior | 2023-07-24 | Semi-Annually | 18 | 1.37% | |
MEDICAMEQ.NS | Ex Dividend Junior | 2023-09-20 | Annually | 3 | 0.02% | |
GULFOILLUB.NS | Dividend Junior | 2023-08-25 | Annually | 11 | 2.19% | |
BBTC.NS | Dividend Junior | 2023-09-22 | Annually | 22 | 0.08% | |
PRESTIGE.NS | Dividend Junior | 2023-09-14 | Annually | 14 | 0.25% | |
KANSAINER.NS | Dividend Junior | 2023-05-25 | Annually | 21 | 0.49% | |
EIHAHOTELS.NS | Dividend Junior | 2023-07-31 | Sporadic | 17 | 0.31% | |
ADVENZYMES.NS | Dividend Junior | 2023-08-04 | Annually | 8 | 0.59% | |
SUBROS.NS | Dividend Junior | 2023-08-22 | Annually | 20 | 0.22% | |
NAHARSPING.NS | Dividend Junior | 2023-09-08 | Annually | 18 | 0.74% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.151 | 1.500 | 6.98 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0 | 1.200 | 0 | 0 | [0 - 0.3] |
returnOnEquityTTM | 0.147 | 1.500 | 9.48 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 0 | 0.800 | -5.00 | -4.00 | [1 - 3] |
quickRatioTTM | 0 | 0.800 | -4.71 | -3.76 | [0.8 - 2.5] |
cashRatioTTM | 0 | 1.500 | -1.111 | -1.667 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 82.77 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 11.30 | 2.00 | 6.23 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 7.82 | 2.00 | 6.09 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.657 | 1.000 | 2.38 | 2.38 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.183 | 1.000 | 8.34 | 8.34 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | 4.35 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 24.96 | 1.000 | 7.58 | 0 | [1 - 100] |
returnOnEquityTTM | 0.147 | 2.50 | 9.67 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 7.82 | 2.00 | 7.39 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 11.30 | 2.00 | 6.23 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 1.506 | 1.500 | 3.29 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0960 | 1.000 | -0.0998 | 0 | [0.1 - 0.5] |
Total Score | 4.24 |
FDC Limited
FDC Limited manufactures and markets pharmaceutical products in India and internationally. The company offers specialized formulations for various therapeutic segments, including anti-infective, gastrointestinal, ophthalmological, vitamins/minerals/dietary supplements, cardiac, anti-diabetes, respiratory, gynecology, dermatology, analgesics, and others; and oral rehydration salts. It provides specialized formulations primarily under the Zifi, Electral, Enerzal, Vitcofol, Pyrimon, Zocon, Zoxan, Zathrin, Zipod, Zefu, Cotaryl, and Mycoderm brand names. The company also offers anti-oxidants, balanced energy drinks, and vitamins and nutraceuticals under the Enerzal, Humyl, Mum Mum 1, Prosoyal, Simyl-LBW, Simyl-MCT, and Zefrich brands. In addition, it provides various active pharmaceutical ingredients. FDC Limited was founded in 1936 and is headquartered in Mumbai, India.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。